Login to Your Account



Northwest's DCVax-L Adds UK Sites in Phase III GBM Program

By Catherine Shaffer
Staff Writer

Thursday, August 23, 2012

The Medicines and Healthcare Products Regulatory Agency of the UK approved a 300-patient Phase III trial of Northwest Biotherapeutics Inc.'s DCVax-L for glioblastoma multiforme (GBM). Phase III is in full swing in the U.S., at 41 clinical sites, but Northwest seeks to expand the trial to international sites, starting in the UK, stating it will save several years' time by not carrying out separate U.S. and European trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription